Search results for " prognostic biomarker"

showing 9 items of 9 documents

Recent Patents on Oxidative Stress-Related Biomarkers in Chronic Heart Failure: The Central Role of Endothelium and Myeloperoxidase

2013

Endothelial cells are key modulators of multiple physiological processes, and their impairment may result in the generation of endothelial dysfunction and ultimately cardiovascular diseases. Under physiologic conditions, reactive oxygen and nitrogen mediators of endothelial cells act to propagate signals driven by different stimuli, by forming molecules with a longer half-life like hydrogen peroxide. Reactive oxygen species (ROS) are constantly produced as a consequence of aerobic metabolism. Under physiologic conditions, their tendency to cause oxidative damage is counterbalanced by the action of antioxidants or oxidant-scavenging enzymes. An imbalance in favour of oxidants leads to oxidat…

Settore BIO/16 - Anatomia UmanaClinical BiochemistryMolecular MedicineChronic heart failure coronary artery disease diagnostic markers endothelial dysfunction endothelium myeloperoxidase oxidative stress prognostic biomarkers serum assaysRecent Patents on Biomarkers
researchProduct

Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoin…

2021

Gastrointestinal stromal tumors (GISTs) represent 1% of all primary gastrointestinal tumors. Immune surveillance is often overcome by cancer cells due to the activation of immunoregulatory molecules such as programmed death protein (PD-1) and its ligand PD-L1, and butyrophilin sub-family 3A/CD277 receptors (BTN3A). Because several studies demonstrated that tumor PD-1 and PD-L1 expression may have a prominent prognostic function, this investigation aimed to discover if soluble forms of these molecules may be useful in predicting survival of metastatic GIST (mGIST) patients. Through specific ad hoc developed ELISA assays not yet available on the market, the circulating PD-1, PD-L1, BTN3A1, an…

PD-L10301 basic medicineCancer ResearchStromal cellSettore MED/06 - Oncologia MedicaArticle03 medical and health sciencesExon0302 clinical medicineImmune systemButyrophilinPD-L1PD-1Medicineprognostic biomarkerReceptorRC254-282butyrophilinsbiologyGiSTbusiness.industrycirculating immune checkpointsNeoplasms. Tumors. Oncology. Including cancer and carcinogensBTN3A1Antitumor immune response BTN3A1 Butyrophilins Circulating immune checkpoints GIST PD‐1 PD‐L1 Prognostic biomarkerantitumor immune response030104 developmental biologyOncology030220 oncology & carcinogenesisCancer cellCancer researchbiology.proteinbusinessGISTCancers
researchProduct

Heat Shock Protein 70 Serum Levels Differ Significantly in Patients with Chronic Hepatitis, Liver Cirrhosis, and Hepatocellular Carcinoma

2014

Members of the heat shock protein 70 (HSP70) family play an important role in assisting protein folding, preventing protein aggregation and transport of proteins across membranes under physiological conditions. Following environmental (i.e., irradiation, chemotherapy), physiological (i.e., cell growth, differentiation), and pathophysiological (i.e., inflammation, tumorigenesis) stress, the synthesis of heat shock proteins (HSPs) is highly up-regulated, whereas protein synthesis in general is reduced. In contrast to normal cells, many tumor entities including hepatocellular carcinoma (HCC) overexpress HSP70, the major-stress-inducible member of the HSP70 family, present it on their cell surf…

medicine.medical_specialtyPathologyCirrhosismedicine.medical_treatmentliver cirrhosisImmunologyInflammationmedicine.disease_causeGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInternal medicinemedicineImmunology and AllergyHCCprognostic biomarker030304 developmental biologyOriginal Research0303 health sciencesChemotherapyserum HSP70business.industryHcc ; Chronic Hepatitis ; Inflammation ; Liver Cirrhosis ; Prognostic Biomarker ; Serum Hsp70medicine.diseasePathophysiology3. Good healthHsp70HCC serum HSP70 prognostic biomarker chronic hepatitis inflammation liver cirrhosisinflammation030220 oncology & carcinogenesisHepatocellular carcinomachronic hepatitismedicine.symptomCarcinogenesisbusinessFrontiers in Immunology
researchProduct

Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls?

2015

Introduction: The discovery of molecular biomarkers and the advent of targeted therapies have led to a radical change in the treatment of several tumors, including NSCLC. In the last few years, the number of molecular biomarkers has rapidly increased, and a growing interest has been recently focused on their potential prognostic and predictive value in clinical settings. Areas covered: This review describes all the molecular biomarkers with prognostic and predictive value in NSCLC, including both clinically approved biomarkers, and emerging biomarkers under investigation in clinical trials. Liquid biopsy and applications of circulating biomarkers are also described. Expert opinion: The onco…

Oncologymedicine.medical_specialtyPathologyLung NeoplasmsOncogene Proteins Fusionmedicine.medical_treatmentClinical BiochemistryNSCLCprognostic biomarkersTargeted therapytissue biopsypredictive biomarkersInternal medicineCarcinoma Non-Small-Cell LungProto-Oncogene ProteinsDrug DiscoveryBiomarkers TumorMedicineHumansBiomarker discoveryLiquid biopsypredictive biomarkerprognostic biomarkerProtein Kinase InhibitorsPredictive biomarkerPharmacologyliquid biopsybusiness.industryDrug Discovery3003 Pharmaceutical Scienceliquid biopsy; NSCLC; predictive biomarkers; prognostic biomarkers; targeted therapy; tissue biopsy; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical ScienceProtein-Tyrosine KinasesPrognosistargeted therapyMolecular biomarkersPredictive valueClinical trialErbB ReceptorsCirculating biomarkersras Proteinsbusiness
researchProduct

Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.

2019

In prostate adenocarcinoma (PCa), distinction between indolent and aggressive disease is challenging. Around 50% of PCa are characterized by TMPRSS2‐ERG (T2E)‐fusion oncoproteins defining two molecular subtypes (T2E‐positive/negative). However, current prognostic tests do not differ between both molecular subtypes, which might affect outcome prediction. To investigate gene‐signatures associated with metastasis in T2E‐positive and T2E‐negative PCa independently, we integrated tumor transcriptomes and clinicopathological data of two cohorts (total n = 783), and analyzed metastasis‐associated gene‐signatures regarding the T2E‐status. Here, we show that the prognostic value of biomarkers in PCa…

OncologyProstate adenocarcinomaMaleCancer Researchmedicine.medical_specialtyOncogene Proteins FusionKaplan-Meier EstimateAdenocarcinomaTMPRSS2MetastasisTranscriptome03 medical and health sciences0302 clinical medicineInternal medicinemedicineBiomarkers TumorHumansPrognostic biomarkerMetastasis ; Personalized Medicine ; Prognostic Biomarker ; Prostate Adenocarcinoma ; Tmprss2-ergNeoplasm MetastasisNeoplasm Stagingbusiness.industryGene Expression ProfilingComputational BiologyProstatic Neoplasmsmedicine.diseasePrognosisImmunohistochemistryGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisImmunohistochemistryPersonalized medicineNeoplasm GradingbusinessErgInternational journal of cancerReferences
researchProduct

Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression.

2014

ABSTRACT Background At diagnosis, identification of reliable biological indicators of prognosis to allow stratification of patients according to different risks is an important but still unresolved aspect in the treatment of Ewing sarcoma (EWS) patients. This study aimed to explore the role of miR-34A expression on prognosis of EWS patients. Patients and methods Specimens from 109 patients with non-metastatic EWS treated at the Rizzoli Institute with neoadjuvant chemotherapy (protocols ISG/SSGIII, EW-1, EW-2, EW-REN2, EW-REN3, EW-PILOT) and 17 metastases were studied. Sixty-eight patients (62%) remained disease-free and 41 (38%) relapsed (median follow-up: 67 months, range 9–241 months). Ex…

AdultMalePrognosiHydro-Lyasemedicine.medical_treatmentSarcoma EwingDisease-Free SurvivalCyclin D1medicineHumansCyclin D1Neoplasm Metastasisprognostic biomarkerNeoadjuvant therapyHydro-LyasesAged 80 and overTissue microarraybiologybusiness.industryProportional hazards modelMedicine (all)Ewing's sarcomaMicroRNAHematologyMiddle Agedmedicine.diseasePrognosisNeoadjuvant TherapyNeoplasm MetastasiGene Expression Regulation NeoplasticMicroRNAsKi-67 AntigenTreatment OutcomeOncologyDrug Resistance NeoplasmKi-67biology.proteinCancer researchKi-67ImmunohistochemistryFemaleSarcomacyclin D1; Ewing sarcoma; Ki-67; miR-34a; prognostic biomarkers; Adult; Aged 80 and over; Cyclin D1; Disease-Free Survival; Drug Resistance Neoplasm; Female; Gene Expression Regulation Neoplastic; Humans; Hydro-Lyases; Ki-67 Antigen; Male; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Sarcoma Ewing; Treatment Outcome; Medicine (all)businessEwing sarcomamiR-34aHumanAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-Cov-2 infection: effect of ACE-2 expression on tumor cells or molecul…

2021

Colorectal cancerSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)medicine.medical_treatmentcolorectal cancermedicine.disease_causeMutually exclusive eventsMolecular oncologyMetastasismolecular oncologymedicinemetastasisprognostic biomarkerLetter to the EditorRC254-282business.industrySettore BIO/16 - Anatomia UmanaNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapymedicine.diseaseMolecular mimicryOncologyTumor reductionCancer researchimmunotherapybusinesscolorectal cancer immunotherapy metastasis molecular oncology prognostic biomarker
researchProduct

Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.

2016

Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of CRC-related liver metastases (CLM), showing conflicting results. This meta-analysis aims to review all the studies reporting survival outcomes (recurrence free survival (RFS), and/or overall survival (OS)) of patients undergoing resection of CLM, stratified according to KRAS and/or BRAF mutation status. Background: Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of CRC-related liver metast…

0301 basic medicineOncologyendocrine system diseasesColorectal cancerLiver metastasimedicine.medical_treatmentColorectal Neoplasmmedicine.disease_cause0302 clinical medicineLiver metastasisHematologyTumorLiver NeoplasmsHematologyPrognosisSurvival RateOncologyLiver Neoplasm030220 oncology & carcinogenesisMeta-analysisKRASColorectal NeoplasmsHumanProto-Oncogene Proteins B-rafmedicine.medical_specialtyPrognostic biomarkerPrognosiResectionBRAFProto-Oncogene Proteins p21(ras)03 medical and health sciencesInternal medicineBRAF; Colorectal cancer; KRAS; Liver metastasis; Prognostic biomarker; Biomarkers Tumor; Colorectal Neoplasms; Humans; Liver Neoplasms; Mutation; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate; Hepatectomy; Oncology; Hematology; Geriatrics and GerontologymedicineKRASBiomarkers TumorHepatectomyHumansneoplasmsSurvival ratebusiness.industrymedicine.diseaseColorectal cancerdigestive system diseasesClinical trial030104 developmental biologyMutationBRAF; Colorectal cancer; KRAS; Liver metastasis; Prognostic biomarker; Biomarkers; Tumor; Colorectal Neoplasms; Humans; Liver Neoplasms; Mutation; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate; Hepatectomy; Oncology; Hematology; Geriatrics and GerontologyHepatectomyGeriatrics and GerontologybusinessBiomarkersCritical reviews in oncology/hematology
researchProduct

Skewed Differentiation of Circulating Vγ9Vδ2 T Lymphocytes in Melanoma and Impact on Clinical Outcome

2016

OBJECTIVE:The aim of this study was to evaluate over time circulating γδ T lymphocytes in melanoma patients in terms of frequency, effector functions, and relationship with clinical stage and evolution, by comparing preoperative values to those obtained at a mean follow-up of 36 months or in the event of recurrence or disease progression, and to those of healthy controls. Also, we correlated the presence of tumor-infiltrating γδ T lymphocytes with clinical evolution of melanoma. RESULTS:Mean frequencies of circulating γδ T cells before and after melanoma removal were very similar and comparable to healthy subjects, but patients who progressed to stage III or IV showed a significantly decrea…

MelanomasMale0301 basic medicineSkin NeoplasmsCellular differentiationmedicine.medical_treatmentSettore MED/19 - Chirurgia Plasticalcsh:MedicineWhite Blood Cells0302 clinical medicineAnimal CellsMedicine and Health SciencesMedicineCytotoxic T cellStage (cooking)lcsh:ScienceMelanomaγδ T lymphocytes melanoma prognostic biomarkerCultured Tumor CellsAged 80 and overMultidisciplinaryT CellsEffectorMelanomaCell DifferentiationReceptors Antigen T-Cell gamma-deltaMiddle AgedPrognosisPhenotypeSurgical OncologyPhenotypeCytokineOncology030220 oncology & carcinogenesisCutaneous MelanomaMelanoma CellsFemaleImmunotherapyBiological CulturesCellular TypesResearch ArticleAdultDeath RatesImmune CellsImmunologyMalignant Skin NeoplasmsSurgical and Invasive Medical ProceduresDermatologyResearch and Analysis Methods03 medical and health sciencesLymphocytes Tumor-InfiltratingPopulation MetricsHumansDemographyAgedNeoplasm StagingSettore MED/04 - Patologia GeneraleBlood CellsPopulation Biologybusiness.industrylcsh:RCase-control studyBiology and Life SciencesCancers and NeoplasmsCell BiologyCell Culturesmedicine.disease030104 developmental biologyCase-Control StudiesPeople and PlacesImmunologylcsh:QClinical ImmunologyClinical MedicinebusinessPLOS ONE
researchProduct